IPIX (Innovation Pharmaceuticals) Cash-to-Debt: 3.63 (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Innovation Pharmaceuticals Cash-to-Debt?

Innovation Pharmaceuticals IPIX Cash-to-Debt is 3.63 as of Sep. 2023.

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Innovation Pharmaceuticals's cash to debt ratio for the quarter that ended in Sep. 2023 was 3.63.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Innovation Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Innovation Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

IPIX's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 6.52
* Ranked among companies with meaningful Cash-to-Debt only.

Innovation Pharmaceuticals  (OTCPK:IPIX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Innovation Pharmaceuticals Cash-to-Debt Related Terms

Innovation Pharmaceuticals Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Innovation Pharmaceuticals Cash-to-Debt Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 2.45 5.45 7.58 5.66

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.60 6.17 5.61 5.66 3.63

IPIX vs AXIM, RNAZ, APTX: Cash-to-Debt Comparison

For the Biotechnology subindustry, Innovation Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovation Pharmaceuticals Cash-to-Debt vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's Cash-to-Debt falls into.


Innovation Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Innovation Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=1.518 / (0.268 + 0)
=5.66

Innovation Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.864 / (0.238 + 0)
=3.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash-to-Debt →
What does a Cash-to-Debt of 3.63 mean?
Innovation Pharmaceuticals (IPIX) has a Cash-to-Debt of 3.63 as of Sep. 2023.
Is Innovation Pharmaceuticals' Cash-to-Debt too high?
Innovation Pharmaceuticals' current Cash-to-Debt is 3.63. The Biotechnology industry median Cash-to-Debt is 6.52. Innovation Pharmaceuticals' value of 3.63 is 44.3% below this industry median.
How does Innovation Pharmaceuticals' Cash-to-Debt compare to AXIM and RNAZ?
Innovation Pharmaceuticals' Cash-to-Debt of 3.63 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 6.52. Innovation Pharmaceuticals' value of 3.63 is 44.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.52, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovation Pharmaceuticals's current Cash-to-Debt of 3.63 is 44.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovation Pharmaceuticals's current Cash-to-Debt is 3.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation Pharmaceuticals stock overvalued right now?
Innovation Pharmaceuticals (IPIX) has a current Cash-to-Debt of 3.63. The current Cash-to-Debt is 3.63 and 44.3% below the Biotechnology industry median of 6.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current Cash-to-Debt is 3.63 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.